Yaohua Pharmaceutical's four major financial indicators hit new highs, shouting that profits have entered an explosive period

New drug company Yaohua Pharmaceutical (6446) held a press conference today. Yaohua Pharmaceutical said that thanks to the continued growth of global sales of its new drug Ropeg for the treatment of polycythemia vera (PV) and essential thrombocytosis (ET), the four core financial indicators of revenue, industry profit, net profit and earnings per share (EPS) in the first three quarters of this year continued to hit new highs.

In the third quarter, Yaohua Pharmaceutical made a profit of 3.13 billion yuan, an annual increase of 168.38%; net profit reached 2.92 billion yuan, an annual increase of 98.45%; EPS reached 7.08 yuan, continuing to hit a new single-quarter high. The cumulative profit of the industry in the first three quarters reached 8.37 billion yuan, an annual increase of 148.65%; the net profit reached 7.6 billion yuan, an annual increase of 113%, and EPS reached 18.43 yuan, which was nearly 1.5 times that of last year.

Yaohua Pharmaceutical stated that its operating growth in the third quarter mainly comes from four major drivers: including the launch of Ropeg injection pens in the United States in July, which provides more convenient medication options, the benefits of expanding the business and medical affairs teams in the United States and Japan are gradually emerging, the marketing and sales strategies continue to be optimized and effective, and the successful delivery of medical scientific information effectively promotes continued increase in market penetration.

Yaohua Pharmaceutical stated that its gross profit margin in the third quarter reached 96.84%, mainly due to the increase in revenue share in the US and Japanese markets, the benefits of the US drug price increase in May being fully reflected in the third quarter, and the positive impact of exchange rate changes. As for the operating profit rate in the third quarter, 40.32%, a decrease from 46.03% in the previous quarter, mainly reflecting the recognition of expenses for employees to subscribe for treasury shares.

Yaohua Pharmaceutical stated that driven by the twin engines of PV and ET, the company will further expand its market and revenue scale. As strong sales growth drives economies of scale and moderately controls operating expenses, profits will enter a period of explosive growth.